A genetically supported drug repurposing pipeline for diabetes treatment using electronic health records
Copyright © 2023 The Authors. Published by Elsevier B.V. All rights reserved..
BACKGROUND: The identification of new uses for existing drug therapies has the potential to identify treatments for comorbid conditions that have the added benefit of glycemic control while also providing a rapid, low-cost approach to drug (re)discovery.
METHODS: We developed and tested a genetically-informed drug-repurposing pipeline for diabetes management. This approach mapped genetically-predicted gene expression signals from the largest genome-wide association study for type 2 diabetes mellitus to drug targets using publicly available databases to identify drug-gene pairs. These drug-gene pairs were then validated using a two-step approach: 1) a self-controlled case-series (SCCS) using electronic health records from a discovery and replication population, and 2) Mendelian randomization (MR).
FINDINGS: After filtering on sample size, 20 candidate drug-gene pairs were validated and various medications demonstrated evidence of glycemic regulation including two anti-hypertensive classes: angiotensin-converting enzyme inhibitors as well as calcium channel blockers (CCBs). The CCBs demonstrated the strongest evidence of glycemic reduction in both validation approaches (SCCS HbA1c and glucose reduction: -0.11%, p = 0.01 and -0.85 mg/dL, p = 0.02, respectively; MR: OR = 0.84, 95% CI = 0.81, 0.87, p = 5.0 x 10-25).
INTERPRETATION: Our results support CCBs as a strong candidate medication for blood glucose reduction in addition to cardiovascular disease reduction. Further, these results support the adaptation of this approach for use in future drug-repurposing efforts for other conditions.
FUNDING: National Institutes of Health, Medical Research Council Integrative Epidemiology Unit at the University of Bristol, UK Medical Research Council, American Heart Association, and Department of Veterans Affairs (VA) Informatics and Computing Infrastructure and VA Cooperative Studies Program.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:94 |
|---|---|
| Enthalten in: |
EBioMedicine - 94(2023) vom: 01. Aug., Seite 104674 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Shuey, Megan M [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antihypertensive Agents |
|---|
| Anmerkungen: |
Date Completed 14.08.2023 Date Revised 26.01.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.ebiom.2023.104674 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM35900797X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM35900797X | ||
| 003 | DE-627 | ||
| 005 | 20240126231905.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ebiom.2023.104674 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1271.xml |
| 035 | |a (DE-627)NLM35900797X | ||
| 035 | |a (NLM)37399599 | ||
| 035 | |a (PII)S2352-3964(23)00239-6 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Shuey, Megan M |e verfasserin |4 aut | |
| 245 | 1 | 2 | |a A genetically supported drug repurposing pipeline for diabetes treatment using electronic health records |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 14.08.2023 | ||
| 500 | |a Date Revised 26.01.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 The Authors. Published by Elsevier B.V. All rights reserved. | ||
| 520 | |a BACKGROUND: The identification of new uses for existing drug therapies has the potential to identify treatments for comorbid conditions that have the added benefit of glycemic control while also providing a rapid, low-cost approach to drug (re)discovery | ||
| 520 | |a METHODS: We developed and tested a genetically-informed drug-repurposing pipeline for diabetes management. This approach mapped genetically-predicted gene expression signals from the largest genome-wide association study for type 2 diabetes mellitus to drug targets using publicly available databases to identify drug-gene pairs. These drug-gene pairs were then validated using a two-step approach: 1) a self-controlled case-series (SCCS) using electronic health records from a discovery and replication population, and 2) Mendelian randomization (MR) | ||
| 520 | |a FINDINGS: After filtering on sample size, 20 candidate drug-gene pairs were validated and various medications demonstrated evidence of glycemic regulation including two anti-hypertensive classes: angiotensin-converting enzyme inhibitors as well as calcium channel blockers (CCBs). The CCBs demonstrated the strongest evidence of glycemic reduction in both validation approaches (SCCS HbA1c and glucose reduction: -0.11%, p = 0.01 and -0.85 mg/dL, p = 0.02, respectively; MR: OR = 0.84, 95% CI = 0.81, 0.87, p = 5.0 x 10-25) | ||
| 520 | |a INTERPRETATION: Our results support CCBs as a strong candidate medication for blood glucose reduction in addition to cardiovascular disease reduction. Further, these results support the adaptation of this approach for use in future drug-repurposing efforts for other conditions | ||
| 520 | |a FUNDING: National Institutes of Health, Medical Research Council Integrative Epidemiology Unit at the University of Bristol, UK Medical Research Council, American Heart Association, and Department of Veterans Affairs (VA) Informatics and Computing Infrastructure and VA Cooperative Studies Program | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Diabetes | |
| 650 | 4 | |a Drug-repurposing | |
| 650 | 4 | |a Glucose | |
| 650 | 4 | |a Hemoglobin A1c | |
| 650 | 4 | |a Mendelian randomization | |
| 650 | 4 | |a Transcriptome-wide association study | |
| 650 | 7 | |a Antihypertensive Agents |2 NLM | |
| 650 | 7 | |a Calcium Channel Blockers |2 NLM | |
| 700 | 1 | |a Lee, Kyung Min |e verfasserin |4 aut | |
| 700 | 1 | |a Keaton, Jacob |e verfasserin |4 aut | |
| 700 | 1 | |a Khankari, Nikhil K |e verfasserin |4 aut | |
| 700 | 1 | |a Breeyear, Joseph H |e verfasserin |4 aut | |
| 700 | 1 | |a Walker, Venexia M |e verfasserin |4 aut | |
| 700 | 1 | |a Miller, Donald R |e verfasserin |4 aut | |
| 700 | 1 | |a Heberer, Kent R |e verfasserin |4 aut | |
| 700 | 1 | |a Reaven, Peter D |e verfasserin |4 aut | |
| 700 | 1 | |a Clarke, Shoa L |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Jennifer |e verfasserin |4 aut | |
| 700 | 1 | |a Lynch, Julie A |e verfasserin |4 aut | |
| 700 | 1 | |a Vujkovic, Marijana |e verfasserin |4 aut | |
| 700 | 1 | |a Edwards, Todd L |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t EBioMedicine |d 2014 |g 94(2023) vom: 01. Aug., Seite 104674 |w (DE-627)NLM244581355 |x 2352-3964 |7 nnns |
| 773 | 1 | 8 | |g volume:94 |g year:2023 |g day:01 |g month:08 |g pages:104674 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.ebiom.2023.104674 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 94 |j 2023 |b 01 |c 08 |h 104674 | ||